Secondary malignancies following cancer chemotherapy

Acta Oncologica

Volumn 33, Issue 6, 1994, Pages 591-598

  Boffetta, Paolo ^a   Kaldor, John M ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CHLORNAPHAZINE; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; MITOMYCIN C; PROCARBAZINE; SEMUSTINE; THIOTEPA; TREOSULFAN; TRIAZIQUONE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; BLADDER NEOPLASMS; HUMAN; LEUKEMIA; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 0027970247     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869409121767     Document Type: Article

References (52)

1. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.
2. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.
3. Quantifying the carcinogenicity of antineoplastic drugs
4. Carcinogenicity of alkylating cytostatic drugs in animals
5. Review—perspectives on occupational exposure to antineoplastic drugs
6. Chemotherapy and immunosuppression for non-malignant conditions
7. Childhood malignancy
8. Standarization of risk ratios
9. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a cancer and leukemia group B study
10. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease
11. Second primary cancers following treatment of Hodgkin's disease
12. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience
13. Summary: multiple primary cancers in Denmark, 1943–80
14. Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935–82
15. Second acute leukemia and other malignancies following treatment for Hodgkin's disease
16. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease
17. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries
18. Risk of second cancers after treatment for Hodgkin's disease
19. Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience
20. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease
21. Leukemia following Hodgkin's disease
22. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease: relation to age, cumulative dose of alkylating agents, and time from chemotherapy
23. Melphalan may be a more potent leukemogen than cyclophosphamide
24. Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with treosulfan (= dihydroxy-busulfan)
25. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience
26. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung
27. Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung
28. Acute nonlymphocytic leukemia after treatment of small cell lung cancer
29. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU)
30. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas
31. Evidence of a treatment dose-response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma
32. The chemotherapy of plasma-cell myeloma and the incidence of acute leukaemia
33. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations
34. Leukemia following chemotherapy for ovarian cancer
35. Second cancer following chemotherapy and radiotherapy. An epidemiological perspective
36. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatos
37. Hematologic neoplasia in patients treated for Hodgkin's disease
38. Second malignancies in Hodgkin's disease: a complication of certain forms of treatment
39. Bladder tumours induced by chlornaphazine: a five-year follow-up study of chlornaphazine-treated patients with polycythaemia
40. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment
41. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma
42. Solid second cancers following Hodgkin's disease
43. Results of treating Hodgkin's disease without policy of laparotomy staging
44. Second malignancies and Hodgkin's disease—The Royal Marsden hospital experience
45. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease
46. Lung cancer in Hodgkin's disease: association with previous radiotherapy
47. Lung cancer following Hodgkin's disease: a case control study
48. Thyroid cancer after treatment of Hodgkin's disease
49. Summary: multiple primary cancers in Connecticut, 1935–82
50. Incidence of second primary cancer following testicular cancer
51. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.
52. Epidemiological studies of the relationship between carcinogenicity and DNA damage